With capecitabine monotherapy, we observed notable reductions in proliferative CD8+ T cells, an immune inhibitory effect, and increases in both CD73+CD8+ T cells and CD226+ NK cells, which could have variable implications for anti-cancer immunity. The gene discussed is CD226; the disease is cancer.